Updated on 5 August 2013
The company however believes that the patent for the salt is valid and will consider appealing the case. The patent for Tykerb is valid till 2019, the company added.
This move by the IPAB comes after the Indian wing of the German drug major Fresenius Kabi moved IPAB challenging the patent of lapatinib and lapatinib ditosylate salt, the key ingredient in Tykerb. The IPAB shot down the salt version of the ingredient, while upholding the patent for lapatinib.